Search
for
Sort by
Research 151–180 of 1000+
- Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Determining meaningful thresholds for evaluating treatment efficacy in patients with alopecia areata
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
- Effectiveness and safety of Baricitinib in alopecia areata: a prospective cohort study
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- Characterization of scalp, eyelash and eyebrow hair regrowth in patients with severe alopecia areata randomized to placebo in brave AA1 and brave AA2 trials
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
- Tofacitinib for the treatment of alopecia areata and variants in adolescents
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Alopecia areata: An update
- Serum vitamin D level is related to disease severity in pediatric alopecia areata
- The in vitro Assembly of Hair Follicle Keratins: Comparison of Cortex and Companion Layer Keratins
- Janus Kinase Inhibitors for Alopecia Areata
- Successful treatment of resistant alopecia areata with a phototoxic dose of ultraviolet A after topical 8‐methoxypsoralen application
- Experience with oral tofacitinib in severe alopecia areata with different clinical responses
- An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
- Platelet-rich plasma in the treatment of alopecia areata: A retrospective evaluation of 17 patients